Talk title: CAR T cell therapy beyond the CD19 paradigm
Michel Sadelain, MD, PhD, is the Director of the Center for Cell Engineering and the incumbent of the Stephen and Barbara Friedman Chair at Memorial Sloan‐Kettering Cancer Center. Dr. Sadelain's research focuses on human cell engineering and cell therapy to treat cancer and hereditary blood disorders. His laboratory has made several seminal contributions to the field of chimeric antigen receptors (CARs), from their conceptualization and optimization to their clinical translation for cancer immunotherapy. In addition to second generation CARs, the Sadelain Laboratory developed artificial antigen presenting cells, auto- and trans-costimulatory engineering strategies, combinatorial antigen approaches, and inhibitory CARs, his group was the first to publish dramatic molecular remissions in patients with chemorefractory acute lymphoblastic leukemia following treatment with CD19-targeted T cells.
« Go Back